This text is a result of machine translation.
IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives
In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow
May 09, 2024 12:18 PM
Aimeike signs distribution cooperation framework agreement with South Korea huons BP
Baijiu plate strength, mouth cellar line exceeds 10%
AMEC: the capital increase and acquisition of part of the equity of hoons biopharma in South Korea have been completed
The investment banking business was strictly supervised, and seven securities companies received fines
China's First Modified New Drug of Docetaxel Successfully Went to the US
Feb 19, 2025 10:41 AM
The first batch of "Mao" concept achievements were released, with a year-on-year growth of more than 50%
The medical and American plate rose sharply
AMEC: the net profit in the first half of the year was 425 million yuan, a year-on-year increase of 188.86%
Aimike's reply to the letter of concern: after obtaining the equity of huons bio, it will not have a significant adverse impact on the company's production and operation
The First Move of the U.S. Postal Service on Cross-Border E-commerce After Trump
Feb 21, 2025 08:19 PM
Shanghai and Shenzhen: The Dual-City Landscape and Corporate Power
Jan 09, 2025 03:35 PM